Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Merck
McKinsey
Medtronic
US Army
Federal Trade Commission
Julphar
Queensland Health
Fuji

Generated: April 27, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 017407

« Back to Dashboard

NDA 017407 describes CATAPRES, which is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from two suppliers. Additional details are available on the CATAPRES profile page.

The generic ingredient in CATAPRES is clonidine. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the clonidine profile page.
Summary for 017407
Tradename:CATAPRES
Applicant:Boehringer Ingelheim
Ingredient:clonidine hydrochloride
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 017407
Mechanism of ActionAdrenergic alpha2-Agonists
Suppliers and Packaging for NDA: 017407
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CATAPRES clonidine hydrochloride TABLET;ORAL 017407 NDA Boehringer Ingelheim Pharmaceuticals Inc. 0597-0006 N 0597-0006-01
CATAPRES clonidine hydrochloride TABLET;ORAL 017407 NDA Boehringer Ingelheim Pharmaceuticals Inc. 0597-0007 N 0597-0007-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.1MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.2MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.3MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Expired US Patents for NDA 017407

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim CATAPRES clonidine hydrochloride TABLET;ORAL 017407-003 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim CATAPRES clonidine hydrochloride TABLET;ORAL 017407-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim CATAPRES clonidine hydrochloride TABLET;ORAL 017407-002 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Daiichi Sankyo
Citi
Federal Trade Commission
AstraZeneca
US Army
Mallinckrodt
Teva
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.